文献速递神经肿瘤神经重症

神经外科加速康复外科方案对胶质瘤患者健康相关生活质量的影响:随机对照试验二次分析

Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial.
PubMed 文献 · J Neurooncol · 2020-06-06

该单中心随机对照试验二次分析纳入65例病理确诊胶质瘤(WHO 2-4级)患者,随机接受围手术期ERAS或常规护理,采用EORTC QLQ-C30/BN20在基线、出院及3、6个月随访评估HRQOL。ERAS组在3个月随访整体生活质量、6个月躯体功能及出院时角色功能方面显示临床相关改善,且多个症状评分显著更低。

要点

  • ERAS组3个月整体生活质量、6个月躯体功能及出院时角色功能有临床相关改善。
  • ERAS组出院时便秘、运动功能障碍、嗜睡、下肢无力及恶心呕吐等症状评分显著更低。
  • 两组6个月无进展生存期及基线HRQOL相似,需多中心研究验证长期获益。

核心结论

  • 神经外科ERAS方案在6个月随访内似可改善胶质瘤患者的功能和症状评分,优于常规护理。

研究设计与样本

  • 单中心随机对照试验的二次分析,患者1:1随机接受围手术期ERAS或常规护理。
  • 共纳入65例病理确诊胶质瘤(WHO 2-4级)患者,ERAS组36例,常规护理组29例。

主要发现

  • 两组6个月无进展生存期和基线HRQOL相似。
  • 评分变化随时间无显著差异,但干预组间差异显著。
  • ERAS组3个月随访整体生活质量、6个月随访躯体功能及出院时角色功能有临床相关改善。
  • ERAS组出院时便秘、运动功能障碍(出院、3和6个月随访)、嗜睡(3和6个月随访)、下肢无力(3个月随访)及恶心呕吐(出院和6个月随访)症状评分显著更低。

临床怎么用

  • 对胶质瘤择期开颅患者,可考虑实施神经外科ERAS方案以改善短期功能状态和症状负担。

局限性

  • 为单中心随机对照试验的二次分析,样本量有限(65例)。
  • 需未来足够效力的多中心研究确认结果并评估长期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A novel neurosurgical enhanced recovery after surgery (ERAS) program shortens postoperative hospital stay and accelerates functional recovery in elective craniotomy patients. There is a need to evaluate the impact of ERAS program on patients' health-related quality of life (HRQOL). METHODS: In a single-center randomized controlled trial, patients were randomized 1:1 to receive perioperative ERAS or conventional care. As a secondary outcome, HRQOL was measured with the EORTC QLQ-C30/BN20 prior to randomization (baseline), at discharge, and at 3- and 6-month follow-up. RESULTS: A total of 65 patients (ERAS: n = 36, conventional care: n = 29) with pathologically confirmed glioma (WHO grade 2-4) were included in the analysis. Progression-free survival at 6 months and HRQOL at baseline were similar between the two groups. Changes of scores did not vary significantly over time, but differed significantly between intervention groups. A clinically relevant better QoL (at 3-month follow-up), physical functioning (at 6-month follow-up) and role functioning (at discharge) was observed in patients in the ERAS group. Symptom scores of constipation (at discharge), motor dysfunction (at discharge, 3- and 6-month follow-up), drowsiness (at 3- and 6-month follow-up), weakness of legs (at 3-month follow-up), and nausea/vomiting (at discharge and 6-month follow-up) were significantly lower in the ERAS group. CONCLUSIONS: The neurosurgical ERAS program seems to improve functioning and symptoms scores in glioma patients within 6-month follow-up compared with conventional care. The intervention has a significant main effect HRQOL changes without significant interaction with time. Future well-powered multicenter studies are warranted to confirm this result and address long-term benefits. This study has been registered in the Chinese Clinical Trial Registry ( http://www.chictr.org.cn/showproj.aspx?proj=16480 ) with registration number ChiCTR-INR-16009662.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Liu B, Liu S, Wang Y, et al. Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial. J Neurooncol. 2020. PMID: 32506368. doi:10.1007/s11060-020-03548-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。